A clinical trial has shown that two therapies made from antibodies harvested from Ebola survivors appear to be improving survival rates among people who receive them, the World Health Organization and the National Institutes of Health announced Monday.

The therapies are a cocktail of three monoclonal Ebola antibodies made by Regeneron Pharmaceuticals and a single monoclonal antibody developed by the National Institute of Allergy and Infectious Diseases, part of the NIH. Regeneron’s cocktail is known as REGN-EB3; the single monoclonal antibody is known as mAb114.

Read the rest…

Source link